LA JOLLA, Calif.—A new
collaborative agreement was signed
between Sanford-Burnham
Medical Research Institute and Mayo Clinic for the
development of a pipeline of therapeutic drugs aimed at a variety of diseases.
Per the agreement, Mayo Clinic scientists and researchers in Sanford-
Burnham's
Conrad
Prebys Center for Chemical Genomics will work together to conduct
early-stage drug discovery, including assay development, high-throughput
screening and lead identification. This arrangement builds on a yearlong pilot
phase and expands on the number and range of drug discovery projects
derived
from Mayo Clinic scientists and conducted at Sanford-Burnham.

"The Mayo Clinic-Sanford-
Burnham collaboration provides an
avenue for Mayo scientists to rapidly translate basic science discoveries into
screening platforms that will enable
new drug discovery and a new paradigm in
drug development," said Dr. Andrew Badley, associate dean of research resources
at Mayo Clinic.